Aggamin Pharmaceuticals LLC

Karyopharm Therapeutics is an innovation-driven pharmaceutical company based in Newton Center, MA. They are dedicated to the discovery, development, and commercialization of medicines aimed at improving the lives of patients with cancer and other major diseases. With a focus on oral Selective Inhibitor of Nuclear Export (SINE) technology, Karyopharm is a leader in addressing the fundamental mechanism of oncogenesis, the process through which healthy cells transform into cancer cells. They have a robust pipeline of four unique drug candidates in clinical development, targeting patients with cancer in both hematologic and solid tumors. At Karyopharm, patients are at the core of their mission. They are committed to developing important new medicines that can make a difference in patients' lives. With ongoing clinical trials for their lead drug candidate and next-generation programs, Karyopharm is actively exploring treatments in earlier lines of treatment, combination trials, and various tumor types across both hematologic and solid tumors. Their dedication to patients and innovative approach to drug development sets them apart in the pharmaceutical industry.Generated from the website

Adecto Pharmaceuticals, Inc. is a preclinical-stage biotechnology company based in Brookline, MA, focused on developing targeted therapies for aggressive ADAM8-positive cancers, along with a companion diagnostic to identify suitable patients. With over 30 years of research, Adecto aims to enhance patient outcomes by addressing the critical drivers of tumor growth and metastasis linked to the ADAM8 protein. Currently, there are no approved therapies or diagnostics for patients with ADAM8-positive tumors, which include various aggressive cancers such as those of the breast, stomach, colon, lungs, liver, and pancreas. Adecto's initial focus is on breast cancer, with plans to expand its therapeutic offerings to other oncology indications in the future. Generated from the website

Opexa Therapeutics is a biotechnology company that specializes in the development of patient-specific cellular therapies for the treatment of autoimmune diseases, such as multiple sclerosis and diabetes. It offers Tovaxin, which is a vaccine for early relapsing multiple sclerosis. The company also offers an adult stem cell program that enables the production of multipotent cells generated from patients white blood cells and provides means to differentiate these stem cells into other tissue types. Opexa Therapeutics offers solutions that minimize the threat of treatment rejection. It operates clinical advisory boards for multiple sclerosis and diabetes that take care of the supervision of related procedures. The company provides products to target individual s disease progression and modification.